Takhzyro 300 mg/2 mL (150 mg/mL) single-dose vial Images
Generic Name: lanadelumab
This medication has been identified as Takhzyro 300 mg/2 mL (150 mg/mL) single-dose vial. It is supplied by Takeda Pharmaceutical Company Limited.
Takhzyro is used in the treatment of Hereditary Angioedema and belongs to the drug class hereditary angioedema agents. Takhzyro 300 mg/2 mL (150 mg/mL) single-dose vial is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Takhzyro
- Generic Name
- lanadelumab
- Strength
- 300 mg/2 mL (150 mg/mL) single-dose vial
- Availability
- Prescription only
- Drug Class
- Hereditary angioedema agents
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Takeda Pharmaceutical Company Limited
- National Drug Code (NDC)
- 47783-0644
More about Takhzyro (lanadelumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: hereditary angioedema agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.